Rationale and Evidence for Human Immunodeficiency Virus Treatment as Prevention at the Individual and Population Levels

Christopher Hoffmann, Joel E. Gallant

Research output: Contribution to journalArticle

Abstract

Individual health benefits of antiretroviral therapy (ART) are becoming clearer. In resource-rich countries, side effects of current ART regimens are minimal. US guidelines recommend ART regardless of CD4 count or viral load. Maintaining an undetectable viral load with ART comes close to eliminating the risk of HIV transmission, leading the US guidelines to recommend universal ART to reduce HIV transmission. Achieving population-level control through treatment as prevention (TasP) may be feasible, but requires considerable investment of resources devoted to HIV testing, linkage to care, ART accessibility, and retention in care. Ongoing studies of TasP will provide insight into achieving meaningful ART coverage.

Original languageEnglish (US)
Pages (from-to)549-561
Number of pages13
JournalInfectious Disease Clinics of North America
Volume28
Issue number4
DOIs
StatePublished - Dec 1 2014

Fingerprint

HIV
Population
Viral Load
Therapeutics
Guidelines
Population Control
Insurance Benefits
CD4 Lymphocyte Count

Keywords

  • Adherence
  • Antiretroviral therapy
  • Epidemic
  • HIV
  • HIV testing
  • Prevention
  • TasP
  • Treatment as prevention

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases
  • Medicine(all)

Cite this

@article{046ddabff2324c18a16ed2d7ca03aa3f,
title = "Rationale and Evidence for Human Immunodeficiency Virus Treatment as Prevention at the Individual and Population Levels",
abstract = "Individual health benefits of antiretroviral therapy (ART) are becoming clearer. In resource-rich countries, side effects of current ART regimens are minimal. US guidelines recommend ART regardless of CD4 count or viral load. Maintaining an undetectable viral load with ART comes close to eliminating the risk of HIV transmission, leading the US guidelines to recommend universal ART to reduce HIV transmission. Achieving population-level control through treatment as prevention (TasP) may be feasible, but requires considerable investment of resources devoted to HIV testing, linkage to care, ART accessibility, and retention in care. Ongoing studies of TasP will provide insight into achieving meaningful ART coverage.",
keywords = "Adherence, Antiretroviral therapy, Epidemic, HIV, HIV testing, Prevention, TasP, Treatment as prevention",
author = "Christopher Hoffmann and Gallant, {Joel E.}",
year = "2014",
month = "12",
day = "1",
doi = "10.1016/j.idc.2014.08.003",
language = "English (US)",
volume = "28",
pages = "549--561",
journal = "Infectious Disease Clinics of North America",
issn = "0891-5520",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Rationale and Evidence for Human Immunodeficiency Virus Treatment as Prevention at the Individual and Population Levels

AU - Hoffmann, Christopher

AU - Gallant, Joel E.

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Individual health benefits of antiretroviral therapy (ART) are becoming clearer. In resource-rich countries, side effects of current ART regimens are minimal. US guidelines recommend ART regardless of CD4 count or viral load. Maintaining an undetectable viral load with ART comes close to eliminating the risk of HIV transmission, leading the US guidelines to recommend universal ART to reduce HIV transmission. Achieving population-level control through treatment as prevention (TasP) may be feasible, but requires considerable investment of resources devoted to HIV testing, linkage to care, ART accessibility, and retention in care. Ongoing studies of TasP will provide insight into achieving meaningful ART coverage.

AB - Individual health benefits of antiretroviral therapy (ART) are becoming clearer. In resource-rich countries, side effects of current ART regimens are minimal. US guidelines recommend ART regardless of CD4 count or viral load. Maintaining an undetectable viral load with ART comes close to eliminating the risk of HIV transmission, leading the US guidelines to recommend universal ART to reduce HIV transmission. Achieving population-level control through treatment as prevention (TasP) may be feasible, but requires considerable investment of resources devoted to HIV testing, linkage to care, ART accessibility, and retention in care. Ongoing studies of TasP will provide insight into achieving meaningful ART coverage.

KW - Adherence

KW - Antiretroviral therapy

KW - Epidemic

KW - HIV

KW - HIV testing

KW - Prevention

KW - TasP

KW - Treatment as prevention

UR - http://www.scopus.com/inward/record.url?scp=84913605288&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84913605288&partnerID=8YFLogxK

U2 - 10.1016/j.idc.2014.08.003

DO - 10.1016/j.idc.2014.08.003

M3 - Article

VL - 28

SP - 549

EP - 561

JO - Infectious Disease Clinics of North America

JF - Infectious Disease Clinics of North America

SN - 0891-5520

IS - 4

ER -